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Abstract
Rationale and Objective: Vascular cell adhesion molecule-1 (VCAM-1) is upregulated in ischemia reperfusion injury (IRI),
persisting after restoration of blood flow. We hypothesized that microparticles of iron oxide targeting VCAM-1 (VCAM-MPIO)
would depict ‘‘ischemic memory’’ and enable in vivo assessment of VCAM-1 expression.
Methodology and Findings: Mice subject to unilateral, transient (30 minutes) renal ischemia and subsequent reperfusion
received intravenous VCAM-MPIO (4.5 mg iron/kg body weight). Contrast agent bound rapidly (,30 minutes) in IRI-kidneys
and appeared as intensely low signal areas by MRI in vivo. Automated segmentation and quantification yielded MPIO
contrast volumes of 59916354610
6 mm
3 in IRI vs.8 7 67610
6 mm
3 in kidneys with no surgical intervention (P,0.001);
9068610
6 mm
3 in IRI kidneys exposed to control (IgG-MPIO) and 625680610
6 mm
3, in IRI kidneys pre-treated with a
blocking dose of VCAM-1 antibody (P,0.001). In keeping with quantitative MRI data, VCAM-1 mRNA expression in IRI was
65-fold higher than in kidneys without surgical intervention (3.0660.63 vs. 0.0560.02, P,0.001). Indeed VCAM-1 mRNA
expression and VCAM-MPIO contrast volume were highly correlated (R
2=0.901, P,0.01), indicating that quantification of
contrast volume reflected renal VCAM-1 transcription. Serial imaging showed VCAM-MPIO accumulation at target within 30
minutes, persisting for $90 minutes, while unbound VCAM-MPIO was cleared rapidly from blood, with sequestration by
mac-3 positive Kupffer cells in the liver and monocyte/macrophages in the spleen.
Conclusions: (1) VCAM-MPIO detected VCAM-1 expression and defined its 3-dimensional distribution, revealing ‘‘ischemic
memory’’ in renal IRI; (2) automated volumetric quantification of VCAM-MPIO accurately reflected tissue levels of VCAM-1
mRNA; and (3) VCAM-MPIO bound rapidly to target with active sequestration of unbound MPIO in the liver and spleen.
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Introduction
Ischemia-reperfusion injury (IRI) is an important pathological
process in acute vascular syndromes including myocardial
infarction,[1,2,3] stroke,[4,5] cardiac surgery[2,6] and organ
transplantation.[7,8] A key feature of IRI is activation of
inflammatory pathways, including the endothelial upregulation
of adhesion molecules that mediate leukocyte slowing, rolling, and
firm adhesion to the vessel wall.[9,10,11,12,13] Since these
adhesion molecules persist on the vascular endothelial surface
even after ischemia itself has resolved, their identification could
represent a functional imprint or ‘memory’ of the prior ischemic
insult.[14] Clinical decision making in acute vascular syndromes is
currently hampered by an inability to define the extent and
distribution of ischemia. The ability to identify such an imprint
non-invasively with magnetic resonance imaging (MRI) could
provide more precise and rapid diagnosis and, potentially, guide
targeted interventions.
VCAM-1 and its ligand, a4b1 integrin (also called very late
antigen-4, VLA-4), are important mediators of leukocyte recruit-
ment and inflammation, including in IRI.[10] We have recently
developed a targeted contrast agent for magnetic resonance
molecular imaging. This agent, comprising antibody-conjugated
microparticles of iron oxide (MPIO), has shown upregulation of
VCAM-1 in a mouse model of cerebral inflammation, artificially
induced by direct injection of interleukin-1.[15]
However, if molecular imaging techniques are to be used for
diagnosis and monitoring response to therapy, it will be important
to establish (1) the sensitivity of detection in more ‘physiological’
conditions and (2) that quantitative contrast effects faithfully reflect
tissue levels of the target molecule. The highly uniform size and
composition of MPIO provides a ‘quantal’ platform for molecular
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report molecular expression within a given tissue. Since VCAM-1
expression is regulated at the level of transcription,[16,17,18,
19,20] we used quantitative real time PCR to test the extent to
which objective 3D-quantification of VCAM-MPIO binding
reflected tissue levels of VCAM mRNA.
In this study, we (1) investigate the ability of targeted-MPIO to
detect VCAM-1 expression non-invasively in-vivo and to define its
3-dimensional distribution in a mouse model of unilateral renal
IRI; (2) test whether objective automated volumetric quantification
of MPIO accumulation, detected by MRI, reflects VCAM-1
messenger RNA expression, measured using quantitative real time
polymerase chain reaction (PCR) and (3) define the early time
course of both specific VCAM-1 MPIO binding to target and
clearance (by the liver and spleen) in order to determine the
optimal imaging window.
Materials and Methods
Antibody conjugation to microparticles of iron oxide
(MPIO)
Purified monoclonal rat anti-mouse antibodies to VCAM-1
(clone M/K2, Cambridge Bioscience) or control IgG-1 (clone Lo-
DNP-1, Serotec) were conjugated to myOne tosylactivated MPIO
(1 mm diameter; iron content 26%) with p-toluenesulphonyl (tosyl)-
reactive surface groups (Invitrogen) according to our previously
established method.[15]
Mouse experimental protocol
This study was undertaken with the approval of the University
of Oxford Clinical Medicine Ethical Review Committee and
procedures were performed in accordance with the UK Home
Office Animals (Scientific Procedures) Act 1986. Male C57BL6/J
(H2
b) mice (12–16 weeks; Charles River) were anesthetized and
following an abdominal incision, each renal pedicle was bluntly
dissected. Ischemia was induced by clamping the left renal pedicle
using a haemostatic microvascular clamp (B-1A, ASSI Corp) for
30 min, while the contra-lateral pedicle was exposed but not
instrumented. Cessation of renal blood flow and subsequent
reperfusion were confirmed by tissue pallor during occlusion and
prompt, uniform return of tissue color after clamp removal.[21]
After 16–18 hr reperfusion, mice were subjected to in-vivo MRI.
All mice received intravenous tail vein injection of either VCAM-
MPIO (n=5) or isotype control IgG-MPIO (n=3) (4.5 mg iron
per kg body weight for both). To determine specificity of VCAM-
MPIO, a further group of mice (n=2) was injected with 0.2 mg of
VCAM-1 antibody per kg body weight to block VCAM-1 binding
sites with subsequent administration of VCAM-MPIO 15 min
later. A control group of mice (n=2), which underwent no surgical
procedure, was also imaged after VCAM-MPIO injection.
In-vivo MRI
In-vivo MRI was carried out on a 9.4-Tesla horizontal magnet
interfaced to a VNMRS DirectDrive MR system (Varian Inc. USA)
using a quadrature-driven birdcage coil (id 33 mm – Rapid
Biomedical, Rimpar, Germany). Mice, anaesthetised with isofluorane
(1.5–1.8% isofluorane in 100% O2– flow 3 l/min), were placed prone
in dedicated animal cradles. Body temperature was maintained at
37uC using a warm air-blanket. ECG and respiration were monitored
continuously throughout the experiment. After scouting, shimming
and pulse-calibration, all mice were subjected to a baseline scan prior
to MPIO administration using a double-gated (with steady-state
maintenance[22]), segmented 3D GE-sequence, optimized to provide
bright-blood and T2
*-contrast (TE/TR =2.5/4.2 ms, 8 k-space lines
per cardiac cycle, TRseg=1 RR-interval ,120–170 ms, FOV=
25.6625.6622 mm, 18 mm axial slice, flip angle 15u, matrix size
2566256696, 1 average). The 3D-GE was repeated at six time points,
covering a total period of ,90 minutes post contrast injection.
MRI Analysis
The external border of each kidney on T2*-weighted images
was masked manually prior to segmentation of ‘low signal’ and
‘high signal’ areas of the image, using ImagePro Plus (version 6.1,
Media Cybernetics, UK). Low signal (MPIO contrast) and high
signal (rapidly flowing blood) areas were defined to be 4 standard
deviations either side of the mean signal intensity of the pre-
contrast kidney for each animal. These parameters were applied in
fully automated fashion to segment each 72-slice sequence that
spanned entire kidneys. Segmented images were reconstructed
using the 3D Constructor plug-in to visualise the spatial
distribution of MPIO binding, with low-signal areas assigned to
the green channel and high signal areas to the red channel. The
resultant voxel volumes were summated and expressed in mm
3.
For serial imaging experiments, signal to noise ratios were
calculated for peripheral organs using automated signal intensity
histograms to quantify the mean signal within each organ of
interest. Noise was calculated using the standard deviation of the
mean background noise.
Histology and immunohistochemistry
Following MRI, mice were terminally anesthetised using
isofluorane and perfusion fixed using 10 ml PBS followed by
10 ml 4% paraformaldehyde via the left ventricle. Kidneys were
cut longitudinally in halves to be snap frozen in liquid nitrogen (for
RNA extraction and VCAM-1 immunocytochemistry) or fixed in
paraformaldehyde and paraffin embedded (for histology). Paraffin
sections of the clamped and unclamped kidney (7 mm thick) were
stained with haematoxylin and eosin and examined for the
presence of MPIO using light microscopy (100 X objective).
Frozen sections were incubated with rat monoclonal antibody to
mouse VCAM-1 (Cambridge Bioscience) (1:50 dilution) overnight
at 4uC and detected using a fluorescent anti-rat Alexa Fluor 488
antibody (Invitrogen). Fluorescence images were captured using a
Zeiss LSM510 laser-scanning confocal microscope (Zeiss). For
immunohistochemistry, liver and spleen sections were stained with
primary rat anti-mouse MAC-3 (BD Pharmingen, 1:100) and
biotinylated polyclonal secondary antibodies (Vector Laboratories,
Burlingame, California) detected using a peroxidase kit (Vector
Laboratories) and 3,39-diaminobenzidine chromogen (DAB)
(Vector Laboratories). Sections were counter-stained with haema-
toxylin. Digital light microscopy (LM) images of stained sections
were captured with a Cool Snap Pro color video camera (Media
Cybernetics) mounted on a light microscope (Leica) (x40 and x100
magnification) using ImagePro Plus image analysis software
(version 4.5.1; Media Cybernetics).
Quantitative, real time, reverse transcription polymerase
chain reaction (qRT-PCR)
Total RNA was extracted from snap-frozen kidneys using the
TRIzol method (Invitrogen) and further purified with an RNeasy
Mini kit (Qiagen, Crawley, UK), according to each manufacturer’s
protocol. Equivalent amounts of purified total RNA were used in
20 mL reverse transcription reactions using a QuantiTect Reverse
Transcription Kit (Qiagen) according to manufacturer’s protocol.
Quantitative Real-time PCR was performed in a StepOne Plus
Real-Time PCR System using TaqMan gene expression assays for
VCAM-1 and GAPDH with TaqMan Gene Expression Master-
In Vivo Quantification of VCAM
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by the comparative threshold cycle (DDCT) method by normalizing
to Glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Ste-
pOne Software version 2.0 (Applied Biosystems) results were
exported to Microsoft Excel for further analysis.
In-vitro sEND-1 cell culture
Mouse endothelioma (sEND-1) cells (8610
5 per 35 mm well)
weretreatedwith0–10 ng/mLmurine-recombinanttumornecrosis
factor alpha (TNF-a, R&D systems, UK) for 20 hours at 37uCt o
induce endothelial VCAM-1 expression. Stimulated cells were
incubated in duplicate with VCAM-1-MPIO or negative control
isotype IgG-1 MPIO for 30 minutes at room temperature with
constant rocking. MPIO binding to cells was assessed by differential
interference contrast imaging using a Zeiss LSM510 laser-scanning
confocal microscope (Zeiss, Welwyn Garden City, UK).
Western immunoblotting
Cellular proteins were extracted using RIPA Buffer (Santa Cruz
Biotechnology, Santa Cruz, CA) and protease inhibitors (Com-
plete Protease Inhibitor Cocktail Tablets, Roche, Burgess Hill,
UK). Proteins were separated by SDS-PAGE, transferred to
polyvinylidene fluoride membranes and incubated at 4uC
overnight with monoclonal rat anti-mouse VCAM-1 antibody
(R&D Systems). After washing, membranes were incubated with
an anti-rat secondary antibody (Vector Laboratories, Peterbor-
ough, UK) for 60 min at room temperature. Following extensive
washing, VCAM-1 protein expression was detected using ECL
Western Blot detection reagents (GE Healthcare, Amersham,
UK), recorded on X-ray film and quantified by densitometry using
ImagePro Plus Software (Media Cybernetics, Silver Spring, MD).
Statistical Methods
Data are expressed as mean 6 SEM and compared by two-tailed
Student’s t-tests. Statistical significance was assigned at P,0.05.
Linear regression analysis was performed using GraphPad Prism 4
(GraphPad Software Inc, La Jolla, USA) to relate cell-bound MPIO
quantification with the dose of TNF-a and for comparing VCAM-1
mRNA expression in the kidneys with MPIO contrast volume.
Results
Serial imaging of in vivo VCAM-MPIO binding and
clearance
In kidneys subjected to IRI, VCAM-MPIO caused a marked
contrast effect that was evident as areas of low-signal intensity in both
the renal cortex and medulla. VCAM-MPIO binding was rapid,
showing contrast effects within 30 minutes, and persisted for the entire
Figure 1. Serial in-vivo MRI at 30, 60 and 90 minutes detects VCAM-MPIO accumulation in renal ischemia-reperfusion injury (IRI). A.
VCAM-MPIO caused a marked contrast effect evident as low-signal in the renal cortex and medulla of the IRI kidney (red box). A lesser degree of
signal loss was also evident in the contra-lateral, sham-operated kidney (green box). B. Irrelevant isotype IgG-MPIO control showed no contrast effect
in either IRI (red box) or sham-operated kidneys (green box) (n=3). C. Pre-treatment of mice with anti-VCAM-1 antibody abolished retention of
VCAM-MPIO in both IRI (red box) and sham-operated (green box) kidneys. In A–C, contrast effects peaked at 60 minutes and were sustained
throughout the imaging protocol. Scale bar =5 mm.
doi:10.1371/journal.pone.0012800.g001
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point for imaging, we undertook serial MRI at 30 minute intervals,
demonstrating that contrast effects were clearly apparent by 30 minutes
and maximal by 60 minutes with persistent specific contrast in the
kidneys at 90 minutes (Figure 2A). Microparticles of iron oxide were
rapidly cleared by the liver and spleen, as indicated by reduction in
signal to noise ratio in those organs within 30 minutes (Figure 2B).
Automated segmentation and quantification of contrast
volume
In order to define the volumetric distribution of MPIO contrast
and obtain a ‘bright blood’ arteriogram, using objective criteria,
we examined signal intensity histograms pre-contrast (Figure 3A)
and 60 minutes post-contrast (Figure 3B). To ensure stringent
segmentation criteria, we imposed a threshold four standard
deviations from the mean for both low signal (iron-based contrast)
and high signal (bright blood). The ability of this signal intensity
algorithm to provide automated segmentation of both iron related
contrast effects (green) and the renal arterial structures (red) from
the same image was tested (Figure 3C).
Quantitative volumetric analysis of binding of
microparticles of iron oxide
Three-dimensional (3D) volumetric maps of contrast were
constructed from the segmented images and related to renal
anatomy, defined by the branching arterial tree (Figure 4).
VCAM-MPIO retention was highly conspicuous in the cortex
and medulla of kidneys that were subject to IRI (Figure 4A, image-
left kidney). There was little or no binding of isotype control IgG-
MPIO in either the IRI or sham operated kidneys (Figure 4B). Pre-
treatment of mice with VCAM-1 antibody prevented VCAM-
MPIO retention in both kidneys (Figure 4C). Similarly, mice that
underwent no surgery and were injected with VCAM-MPIO
showed very little MPIO binding (Figure 4D). There was sparse,
but definite, binding of MPIO in sham operated kidneys
(Figure 4A, image-right kidney). Kidneys subject to IRI
(59916354610
6 mm
3) showed a 69-fold increase in VCAM-
MPIO contrast compared to kidneys with no surgical intervention
(8767610
6 mm
3, P,0.001) (Figure 5). Contra-lateral sham
operated kidneys showed modest, but definite contrast effects
(17406528610
6 mm
3, P,0.01) while pre-treatment with VCAM-
1 antibody effectively blocked VCAM-MPIO accumulation in IRI
kidneys (625680610
6 mm
3, P,0.001). Virtually no contrast effect






Quantitative RT-PCR analysis of VCAM-1 mRNA
expression
To test whether quantitative VCAM-MPIO contrast measurements
reflected tissue levels of target, VCAM-1 mRNA expression in kidneys
Figure 2. Signal to noise ratios and area of contrast effect as functions of time. A. Contrast uptake of VCAM-MPIO (low signal areas) was
evident in both clamped & sham operated kidneys by 30 minutes, and was maximal by 60 minutes. Contrast was stable from 60 to 90 minutes post
contrast-injection. B. Signal to noise ratio (SNR) was calculated for intra-abdominal organs. SNR in the liver fell steeply within the first 30 minutes
reaching steady state by 60 min post-contrast administration.
doi:10.1371/journal.pone.0012800.g002
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higher in clamped kidneys compared to sham operated kidneys
(3.0660.63 vs. 0.2560.08, P,0.01) and 65-fold higher than kidneys
without surgical intervention (0.0560.02, P,0.001). VCAM-1 mRNA
expression in sham-operated kidneys was significantly upregulated
compared to kidneys with no surgical intervention (P,0.05) (Figure 5).
VCAM-1 mRNA expression and VCAM-MPIO contrast volume
were highly correlated (R
2=0.901, P,0.01) (Figure 6).
Distribution of VCAM-1 and microparticles of iron oxide
on histology
On microscopic inspection of IRI kidneys, VCAM-MPIO were
adherent to the vessel wall, either singly or in small clusters, of the
peritubular capillaries (Figure 7A). MPIO retention was not
associated with local infarction or haemorrhage. Quantification of
MPIO under light microscopy (Figure 7B) confirmed the
quantitative relationships determined by in vivo MRI. VCAM-1
immunofluorescence was confined to vascular structures without
expression in the renal tubules and in association with VCAM-1
MPIO retention (Figure 7C).
In order to demonstrate that the IRI in this model induced cellular
inflammation, kidneys from additional mice were immunostained for
Gr-1, demonstrating neutrophil accumulation 24 hours after injury
in the IRI mice, but not in the uninjured control (Figure S1).
Unbound MPIO were sequestered in cells that stained positively for
MAC-3 in both liver (peri-sinusoidal, Kupffer cells; Figures 8A & B)
and spleen (monocyte/macrophages; Figures 8C & D).
Discussion
We provide evidence for a non-invasive in-vivo molecular
magnetic resonance imaging approach for quantification of
VCAM-1, a key mediator of inflammation. Applied in a mouse
model, this technique enabled the identification of ischemia-
reperfusion injury in kidneys and described the 3-dimensional
anatomical distribution of inflammation in relation to the renal
arterial tree. We report an objective segmentation technique for
automated quantification of the contrast effect and confirm that
this faithfully reflects tissue levels of VCAM-1 transcript using real
time quantitative real time RT-PCR. This approach therefore
Figure 3. Automated segmentation and quantification of MPIO accumulation. A. Pre-contrast signal intensity histogram showing mean
(dashed line) and 4 standard deviations from the mean into the black spectrum (green) and 4 standard deviations from the mean into the white
spectrum (red). The arrow indicates a peak in the white spectrum corresponding to the intensely bright signal from the renal artery. B. Signal
intensity histogram 60 minutes post-contrast shows a leftward shift in the mean towards the black spectrum (dashed line) as a result of the presence
of MPIO in the kidney. In this post-contrast spectrum, dark pixels 4 standard deviations from the original mean were designated to show contrast
effects for the purposes of segmentation. The bright signal from flowing blood in the renal artery is unaltered by MPIO (arrow). C. Automated
histogram-based segmentation of MPIO contrast effects (green, top panel) and the renal artery (red, bottom panel) from the same slice.
Segmentation enabled 3D volumetric quantification and reconstruction.
doi:10.1371/journal.pone.0012800.g003
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utility in the depiction of a persisting physiological consequence of
recent ischemia. In acute vascular syndromes, such a tool, to
define ‘volume at risk’, could identify high-risk patients and inform
on response to treatment, including in the evaluation of new
therapies.
Figure 4. 3D reconstruction of segmented kidneys. A. VCAM-MPIO contrast (green) was abundant and in both the medulla and cortex of IRI
kidneys (image-left) and to a lesser extent in sham-operated kidneys (image-right). B. In mice that underwent an identical protocol, there was little to
no binding of the isotype IgG-MPIO in either kidney. C. Similarly, there was little to no VCAM-MPIO retention in either kidney in mice that underwent
no surgery (n=2) or D. in mice pre-treated with anti-VCAM-1 antibody prior to contrast administration.
doi:10.1371/journal.pone.0012800.g004
Figure 5. Quantitative volumetric analysis of MPIO binding. VCAM-MPIO related contrast effects were significantly upregulated in clamped
versus unclamped kidneys (n=5, ** P,0.01). Blocking with anti-VCAM-1 antibody resulted in significantly less contrast volume (n=2, ***P,0.001).
Unclamped kidneys showed significant contrast volume compared to both sham operated kidneys in animals given non-specific isotype IgG-MPIO
(n=3, ***P,0.001) as well as animals given anti-VCAM-1 prior to VCAM-MPIO administration (n=2, **P,0.01).
doi:10.1371/journal.pone.0012800.g005
In Vivo Quantification of VCAM
PLoS ONE | www.plosone.org 6 September 2010 | Volume 5 | Issue 9 | e12800Figure 6. MPIO-contrast volume reflects VCAM-1 mRNA expression in tissue. VCAM-1 mRNA expression was 12-fold higher in clamped
kidneys versus sham operated kidneys (n=5, P,0.01). VCAM-1 mRNA expression in sham operated kidneys was significantly upregulated compared
to no surgery animals (P,0.05). VCAM-1 mRNA expression and VCAM-MPIO related contrast volume was highly correlated (R
2=0.901).
doi:10.1371/journal.pone.0012800.g006
Figure 7. Histology. A, Haematoxylin & eosin stained section of IRI kidney with VCAM-MPIO confined to vascular spaces in peritubular capillaries
(black arrows). A small cluster of MPIO is present (Inset) B. VCAM-MPIO retention was significantly upregulated in clamped kidneys versus sham
operated kidneys (n=2, *P,0.05) (6 fields of view per kidney, magnification: 100X) C, VCAM-1 immunofluorescence revealing VCAM-1 expression in
vessels, but not in tubular cells. VCAM-MPIO bearing the same antibody that was used as the primary for VCAM-1 immunofluorescence (pink arrows)
appear as intensely bright spheres (white arrows).
doi:10.1371/journal.pone.0012800.g007
In Vivo Quantification of VCAM
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The diagnostic utility of molecular imaging is enhanced if the
contrast effects reflect tissue levels of target, since such quantitative
imaging would potentially allow severity of disease to be
determined and response to treatment monitored. VCAM-1 has
been imaged previously using MPIO;[15] nanoparticles of iron
oxide;[23] and acoustic microbubbles[24,25] Although the
contrast effects can be quantified, these earlier studies did not
investigate whether there was a quantitative relationship between
non-invasive contrast measurements and tissue levels of target.
Micron-size range iron oxide-based molecular imaging probes
provide both greatly enhanced sensitivity due to their high iron
content and, because of their uniform size and composition, an
opportunity for quantitative evaluation. Since VCAM-1 expres-
sion is regulated at the level of transcription,[16,17,18,19,20] we
used quantitative real time RT-PCR to measure tissue levels of
VCAM-1 mRNA in the kidneys, and demonstrated a close
correlation between in vivo VCAM-MPIO retention and ex vivo
measurement of VCAM-1 mRNA. To provide further confirma-
tion of the quantitative link from mRNA to MPIO binding, we
stimulated sEND-1 cells with graded doses of TNF-a, showing
strong correlations between mRNA, protein and MPIO retention
(Figure S2). Therefore, MRI can be used to attain quantitative
reporting that is usually only achievable with nuclear techniques,
e.g. positron emission tomography.[26]
Sensitivity and Dynamic Range
Renal ischemia is known to cause inflammation at sites distant
to the ischemic tissue and has been implicated in injury to the
liver,[27] lungs[28], brain[29] and heart.[30] The mechanisms are
not fully understood, but mediators may include interleukin-6,
since the pulmonary inflammatory response was attenuated in IL-
6 knockout mice.[28] In the model used here, the high degree of
sensitivity provided by MPIO enabled the detection of inflamma-
tion (confirmed with real time RT-PCR), remotely in the contra-
lateral kidney, which had not been exposed to ischemic injury.
This intermediate inflammatory level was detectable with VCAM-
MPIO allowing demonstration of both the sensitivity and dynamic
range of this molecular imaging technique.
Molecular imaging platform
The MPIO contrast agent provides a platform approach to
molecular MRI that allows the substitution of alternative ligands
with specificity for a range of endovascular targets.[31] We have
previously demonstrated the potential to target VCAM-1 or P-
selectin in isolation and have identified synergistic effects of dual-
targeted MPIO for bindingunder conditionsof high shear.[32] Van
Kasteren et al have generated saccharide-based synthetic ligands
that bind with high affinity to selectins, and which have been
applied to molecular MRI in the brain.[33] Indeed, P-selectin is an
attractive target for acute inflammation imaging, including
‘‘ischemic memory’’, since the synthesized protein is stored within
the Weibel-Palade bodies of endothelial cells and can be expressed
on the cell-surface within minutes by transportation to the plasma
membrane.
Microparticles of iron oxide: kinetics and distribution
High ‘target to background’ contrast benefits from rapid onset
of binding at target combined with swift clearance from the blood
pool. Unlike contrast agents that need to be concentrated within
cells or to permeate tissue beyond the vasculature, MPIO binding
to the endothelium is rapid, occurring within minutes. Further-
more binding is directly dependent on its interaction with a highly
accessible target without intervening processes (e.g. cell membrane
transporter function, vessel permeability, tissue diffusion) that have
the potential to confound quantitative reporting of the molecular
target. Rapid specific accumulation at sites of inflammation (within
30–60 minutes) combined with clearance to the liver (within 30
minutes) recommended the 60 minute time point as optimal for
determination of contrast effects in this model. Therefore the size
and physical properties of MPIO confer both contrast sensitivity
and favourable binding and clearance kinetics.
Figure 8. Representative images of MAC-3 immunostaining for macrophages. (A) liver and (B) spleen (haematoxylin counterstain,
magnification x 40). Panels C and D show co-localisation of MPIO within cells that stained positively for MAC-3 in (C) liver and (D) spleen
(magnification x 100).
doi:10.1371/journal.pone.0012800.g008
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The molecular imaging approach described here targets
molecules expressed on activated vascular endothelium. Ligand-
conjugated MPIO are designed to mimic the binding of peripheral
blood leukocytes, but are not dependent on leukocyte binding per
se. As a consequence, binding at a site of target up-regulation can
be rapid, a property that would be valuable in the context of a
clinical contrast agent. An alternative approach has been to use
cells loaded with MPIO as Trojan horses and to utilise MRI to
follow their accumulation according to the trafficking and
distribution of these cells. This has been applied to track stem
cells[34,35,36] and macrophages.[37] The time course of
accumulation of such cells is much longer than for the ligand-
conjugated MPIO, so that they are potentially better suited
tracking chronic processes and regenerative therapies than the
acute inflammatory process exemplified by IRI.
Limitations
Short-term ill effects of MPIO were not seen in mice. We have
previously reported the bio-distribution of 1.0 mm diameter
MPIO, showing a lack of retention in the kidneys and lungs at
both 30 minutes and 24 hours.[38] The MPIO used here were
non-biodegradable and are not suitable for use in humans.
However, iron-oxide containing contrast media are already in
clinical use and it should be feasible to synthesize biodegradable
particles.[39,40] Before clinical use is contemplated, it will clearly
be necessary to undertake a full toxicological evaluation, including
the analysis of MPIO effects on liver and kidney function as well as
the potential of antibody-conjugated MPIO to elicit an immune
response in the recipient. The last possibility could be ameliorated
by the use of ‘humanised’ antibodies.
Conclusions
VCAM-MPIO detected VCAM-1 expression and defined its 3-
dimensional distribution, revealing ‘ischemic memory’ in mouse
kidneys. Furthermore, automated volumetric quantification of
MPIO accurately reflected tissue levels of VCAM-1 mRNA across
a biologically relevant dynamic range, providing evidence for
quantitative molecular magnetic resonance imaging.
Supporting Information
Figure S1 VCAM-1 molecular imaging in this study was
intended to reveal expression of the pro-inflammatory mediator
VCAM-1. In order to demonstrate that the degree of ischemia-
reperfusion injury (IRI) would eventually lead to a cellular
inflammatory response, kidneys subject to 30 minutes ischemia
and 24 hours reperfusion were compared to unoperated controls.
A, non-ischemic kidney without inflammatory cell infiltration. B,
immunostaining (brown) for Gr-1, demonstrating neutrophil
infiltration by 24 hours.
Found at: doi:10.1371/journal.pone.0012800.s001 (1.39 MB
TIF)
Figure S2 Increased VCAM-MPIO retention reflects VCAM-1
mRNA and protein levels in vitro. A, VCAM-MPIO retention
increased in a dose dependent manner in sEND-1 cells following
TNF-a stimulation for 24 hours in vitro (n=4/group, R2 =0.88).
B, VCAM-1 mRNA expression was 6-fold higher in sEND-1 cells
treated with 10 ng/ml TNF-a (black bar) versus cells treated with
2 ng/ml (gray bar, **P,0.01) and 14-fold higher than unstimu-
lated cells (white bar, ***P,0.001). C, VCAM-1 protein, assessed
semi-quantitatively, was 2-fold higher in sEND-1 cells treated with
10 ng/ml TNF-a (black bar) versus cells treated with 2 ng/ml
(gray bar, *P,0.01). VCAM-1 expression was 7-fold higher in
cells treated with 2 ng/ml TNF-a versus unstimulated cells (white
bar, *P,0.01).
Found at: doi:10.1371/journal.pone.0012800.s002 (0.24 MB
TIF)
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